

CLAIMS

423194

We claim:

Sub B

1. An isolated substantially homogeneous *mpl* ligand polypeptide.
2. The *mpl* ligand polypeptide of Claim 1 selected from the group consisting of
 - (a) a fragment polypeptide;
 - (b) a variant polypeptide; and
 - (c) a chimeric polypeptide.
3. The *mpl* ligand polypeptide of Claim 1 selected from the group consisting of
 - (a) the polypeptide that is isolated from a mammal;
 - (b) the polypeptide that is made by recombinant means; and
 - (c) the polypeptide that is made by synthetic means.
4. The *mpl* ligand polypeptide of Claim 1 selected from the group consisting of
 - (a) the polypeptide that is human; and
 - (b) the polypeptide that is non-immunogenic in a human.
5. An isolated substantially homogeneous *mpl* agonist characterized in that:
 - (a) the agonist stimulates the incorporation of labeled nucleotides (³H-thymidine) into the DNA of IL-3 dependent Ba/F3 cells transfected with human *mpl* P; or
 - (b) the agonist stimulates ³⁵S incorporation into circulating platelets in a platelet rebound assay.

Sub B

6. A fragment polypeptide according to Claim 2, wherein the amino acid sequence of the polypeptide comprises amino acid residues 1 to X of Fig. 1 (SEQ ID NO: 1), where X is selected from the group 153, 164, 191, 205, 207, 217, 229, 245 and 332.
7. A fragment polypeptide according to Claim 6, wherein the amino acid sequence of the fragment polypeptide comprises

a
a
a

SPAPPACDLRVLSKLLRDSHVL
HSRLSQCPEVHPLPTPVLLPAVDF
SLGEWKTQMEETKAQDILGAVTL

(SEQ ID NO: 71)
(SEQ ID NO: 72)
(SEQ ID NO: 73)
(SEQ ID NO: 74)

LLEGVMAARGQLGPTCLSSLL (SEQ ID NO: 75)
GQLSGQVRLLL GALQS (SEQ ID NO: 76)
LLGTQLPPQGRRTTAHKDPNAIF (SEQ ID NO: 77)
LSFQHLLRGKVRFLMLVGGSTLCVR (SEQ ID NO: 78)

8. The polypeptide of Claim 6 that is unglycosylated.

9. An isolated substantially homogeneous *mpl* ligand polypeptide sharing at least 80% sequence identity with the polypeptide of Claim 6.

10. The polypeptide of Claim 9 wherein X is 153.

11. An isolated polypeptide encoded by a nucleic acid having a sequence that hybridizes under moderately stringent conditions to the nucleic acid molecules having a nucleic acid sequence provided in Fig. 1 (SEQ ID NO: 2).

12. The polypeptide of Claim 11 that is biologically active.

13. The polypeptide of Claim 1 selected from the group hML, hML153, hML(R153A, R154A), hML2, hML3, hML4, mML, mML2, mML3, pML, and pML2.

14. A chimera comprising the *mpl* ligand of Claim 6 fused to a heterologous polypeptide.

15. The chimera of Claim 14 wherein the heterologous polypeptide is an immunoglobin polypeptide.

16. The chimera of Claim 14 wherein the heterologous polypeptide is an interlukin polypeptide.

17. A chimera comprising the N-terminus residues 1 to about 153 to 157 of hML substituted with one or more, but not all, of the human EPO residues added or substituted into the N-terminus residues of hML at positions corresponding to the alignment shown in Fig. 10.

18. An antibody that is capable of binding the *mpl* ligand polypeptide of Claim 6.

19. A hybridoma cell line producing the antibody of Claim 17.
20. An isolated nucleic acid molecule encoding the *mpl* ligand polypeptide of Claim 1.
21. An isolated nucleic acid molecule encoding the *mpl* ligand polypeptide of Claim 6.
22. An isolated nucleic acid molecule comprising the open reading frame nucleic acid sequence shown in Fig. 1 (SEQ ID NO: 2).
23. The isolated nucleic acid molecule of Claim 20 encoding a *mpl* ligand polypeptide selected from the group hML, hML153, hML(R153A, R154A), hML2, hML3, hML4, mML, mML2, mML3, pML, and pML2.
24. An isolated nucleic acid molecule selected from the group consisting of
 - (a) a cDNA clone comprising the nucleotide sequence of the coding region of the *mpl* ligand gene;
 - (b) a DNA sequence capable of hybridizing under stringent conditions to a clone of (a); and
 - (c) a genetic variant of any of the DNA sequences of (a) and (b) which encodes a polypeptide possessing a biological property of a naturally occurring *mpl* ligand polypeptide.
25. An isolated DNA molecule having a sequence capable of hybridizing to a DNA sequence provided in Fig. 1 (SEQ ID NO: 2) under moderately stringent conditions, wherein the DNA molecule encodes a biologically active *mpl* ligand polypeptide.
26. The nucleic acid molecule of Claim 23 further comprising a promoter operably linked to the nucleic acid molecule.
27. An expression vector comprising the nucleic acid sequence of Claim 23 operably linked to control sequences recognized by a host cell transformed with the vector.
28. A host cell transformed with the vector of Claim 27.
29. A method of using a nucleic acid molecule encoding the *mpl* ligand polypeptide to effect production of the *mpl* ligand polypeptide comprising culturing the host cell of Claim 28.

30. The method of Claim 29 wherein the *mpl* ligand polypeptide is recovered from the host cell.
31. The method of Claim 29 wherein the *mpl* ligand polypeptide is recovered from the host cell culture medium.
32. A method of determining the presence of *mpl* ligand polypeptide, comprising hybridizing DNA encoding the *mpl* ligand polypeptide to a test sample nucleic acid and determining the presence of *mpl* ligand polypeptide DNA.
33. A method of amplifying a nucleic acid test sample comprising priming a nucleic acid polymerase reaction with nucleic acid encoding a *mpl* ligand polypeptide.
34. A composition comprising the *mpl* ligand polypeptide of Claim 1 and a pharmaceutically acceptable carrier.
35. A method for treating a mammal having or at risk for thrombocytopenia comprising administering to a mammal in need of such treatment a therapeutically effective amount of the composition of Claim 34.
36. The composition of Claim 34 further comprising a therapeutically effective amount of an agent selected from the group consisting of a cytokine, colony stimulating factor, and interleukin.
37. The composition of Claim 36 wherein the agent is selected from LIF, G-CSF, GM-CSF, M-CSF, EPO, IL-1, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9 and IL-11.

Add B⁶